$IMLFF Strengthens Board With Appointment of Experienced Biotech Executive

InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems is pleased to announce the appointment of Adam Cutler to the Board of Directors.

Adam Cutler is currently Senior Vice President of Corporate Affairs at Arbutus Biopharma and previously was a Managing Director at The Trout Group LLC and Trout Capital LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. Mr. Cutler spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities, with prior analytical and consulting experience at The Frankel Group and Ernst & Young, Healthcare Consulting. Mr. Cutler holds a BA in Economics from Brandeis University.

“InMed is extremely pleased with the addition of Adam to our Board of Directors,” says Paul Brennan, Chief Executive Officer of InMed. “Adam has over 19 years of experience in the global healthcare industry where he successfully held senior leadership positions in various roles from Equity Research, Corporate Affairs and Strategies, Investor Relations and Consulting. Adam earned a reputation as a top-ranked biotechnology sell-side analyst and advisor, with extensive knowledge of biotech product development, the global healthcare environment, and the US financial community. I believe this experience will be critical in guiding InMed’s strategic planning and to help InMed achieve its corporate goals.”

“I am pleased to join the InMed board,” said Adam Cutler. “InMed’s platform technology is an intriguing and unique approach to developing phytochemicals and phytocannabinoids. I am excited about the potential of InMed’s early development programs in epidermolysis bullosa and glaucoma, and I look forward to working closely with the Management Team and the rest of the Board members to ensure the optimal execution of the company strategy.”

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.